Erasca, Inc. Common Stock
ERAS
$18.29
+14.24%
Erasca, Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, a notoriously difficult-to-treat area of oncology. The company is a niche player in the competitive biotechnology sector, distinguished by its focused pipeline of modality-agnostic programs targeting key nodes, RAS directly, and treatment-emergent escape routes within this critical pathway. The current investor narrative is driven by significant clinical milestones and data readouts for its lead programs, ERAS-0015 and ERAS-4001, which have catalyzed a dramatic re-rating of the stock, though recent volatility underscores the binary nature of clinical-stage biotech investing and the market's sensitivity to trial updates.…
ERAS
Erasca, Inc. Common Stock
$18.29
Investment Opinion: Should I buy ERAS Today?
Rating & Thesis: Hold. ERAS is a high-risk, high-reward clinical-stage biotech suitable only for speculative capital, where the current price reflects a balanced risk/reward profile following a significant correction, but lacks a clear near-term catalyst for a sustained move higher. The positive analyst sentiment (Overweight/Buy ratings) is offset by the absence of concrete price targets and the recent demonstration of extreme volatility.
Supporting Evidence: The stock trades at deeply negative valuation multiples (PE of -8.45, Forward PE of -26.02), which are meaningless for a pre-revenue company but underscore the speculative premium embedded in the share price. The 30% one-month rebound suggests some technical stabilization, but the stock remains 38% below its 52-week high. The strong balance sheet (current ratio of 10.04, D/E of 0.145) and low debt are positive, but the aggressive cash burn (-$95.6M TTM FCF) is a pressing concern. The lack of a consensus price target from analysts makes quantifying upside difficult.
Risks & Conditions: The thesis would upgrade to a Buy on: 1) Positive interim clinical data for ERAS-0015 or ERAS-4001 that validates the mechanism, 2) A partnership or licensing deal that provides non-dilutive funding and validation, or 3) A successful equity raise at a premium that extends the cash runway beyond 18 months. The thesis would downgrade to a Sell on: 1) Negative clinical data from a lead program, 2) A dilutive equity offering below the current market price, or 3) Quarterly cash burn accelerating beyond $30M. Relative to its own volatile history and the binary nature of its pipeline, the stock appears fairly valued at current levels, pricing in significant hope but also considerable clinical risk.
Sign up to view all
ERAS 12-Month Price Forecast
The outlook for ERAS is bifurcated and entirely event-driven. The neutral stance reflects the stock's position after a massive rally and subsequent sharp correction, where near-term catalysts are balanced against high execution risk. The strong liquidity position provides a temporary buffer, but the cash burn necessitates a capital raise, which will be dilutive unless accompanied by positive clinical news. The base case of continued volatility within a $10-$18 range is most probable, as the market awaits concrete data. The stance would upgrade to bullish on a clean equity raise above current prices or positive clinical data, and downgrade to bearish on any clinical setback or a financing below $10 per share.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Erasca, Inc. Common Stock's 12-month outlook, with a consensus price target around $23.78 and implied upside of +30.0% versus the current price.
Average Target
$23.78
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$15 - $24
Analyst target range
Insufficient analyst coverage data is available to form a quantitative consensus, as the provided data only includes three analysts' estimates for future EPS and revenue but lacks explicit price targets or recommendation distributions. The limited number of covering analysts and the absence of a published consensus target price suggest this is a specialized, clinical-stage name with limited institutional following, which can lead to higher volatility and less efficient price discovery. The available institutional ratings from firms like JP Morgan and Guggenheim are uniformly positive (e.g., Overweight, Buy), indicating strong specialist conviction, but without a quantified target range, it is impossible to gauge the implied upside or the dispersion of views that would signal the level of uncertainty surrounding the stock's clinical outcomes.
Bulls vs Bears: ERAS Investment Factors
The bull and bear cases for ERAS are starkly defined by its clinical-stage status. The bull case, supported by a 983% annual gain and strong specialist analyst conviction, hinges entirely on the successful development of its RAS/MAPK pathway pipeline, particularly ERAS-0015 and ERAS-4001. The bear case, evidenced by a recent -59.5% drawdown and persistent cash burn, highlights the binary, high-risk nature of betting on unproven therapies. Currently, the bear side presents stronger near-term evidence due to the stock's violent correction and lack of fundamental financial anchors. The single most important tension in the investment debate is the sufficiency of the company's $74.2 million cash balance to fund operations through the next critical clinical catalysts without resorting to highly dilutive financing, which would pressure the stock price even if trial data is positive.
Bullish
- Dramatic Clinical Re-Rating: The stock's 983.3% 1-year price change reflects a massive re-rating driven by positive clinical milestones for lead programs ERAS-0015 and ERAS-4001. The move from $1.21 to a high of $24.28 demonstrates significant market conviction in the pipeline's potential, with the stock still up 329.6% over the last six months despite a recent correction.
- Strong Specialist Analyst Conviction: Available institutional ratings from firms like JP Morgan and Guggenheim are uniformly positive (Overweight/Buy), indicating strong specialist conviction in the company's focused RAS/MAPK pathway strategy. This expert backing is a critical signal in a complex, clinical-stage biotech with limited analyst coverage.
- Robust Balance Sheet & Liquidity: The company maintains a fortress balance sheet with a current ratio of 10.04 and minimal debt (debt-to-equity of 0.145). This provides a significant cash runway to fund clinical development without immediate dilution risk, a key advantage for a pre-revenue biotech.
- Recovering Technical Momentum: After a sharp -59.5% drawdown from April highs, the stock has shown resilience, rebounding 30.0% over the past month. Trading at $14.95, it is consolidating well above its 52-week low of $1.21, suggesting the primary uptrend may be re-establishing itself.
Bearish
- Severe Clinical Trial Volatility: The stock's extreme volatility, including a -59.5% maximum drawdown in recent months, underscores its binary, event-driven nature. The price collapse from $22.47 to $9.90 in late April 2026 is a stark reminder of the high risk associated with clinical data readouts and trial updates.
- Aggressive Cash Burn & No Revenue: The company is pre-revenue with a trailing twelve-month free cash flow burn of -$95.6 million and a quarterly operating cash flow of -$21.7 million. With Q4 2025 cash of $74.2 million, the runway is finite, raising the near-term risk of dilutive equity financing if clinical timelines extend.
- Negative Valuation Metrics & Losses: All traditional valuation metrics are negative or inapplicable: trailing PE of -8.45, forward PE of -26.02, and EV/EBITDA of -8.47. The lack of a Price-to-Sales ratio (PS=0) highlights the complete dependence on future, unproven clinical success for valuation.
- Limited Analyst Coverage & Price Discovery: With only 3 analysts providing estimates and no published consensus price target, the stock suffers from inefficient price discovery and higher volatility. The absence of a quantified target range makes it difficult to gauge fair value and implied upside, increasing investment uncertainty.
ERAS Technical Analysis
The stock is in a powerful, sustained uptrend over the past year, evidenced by a staggering 983.3% 1-year price change. Currently trading at $14.95, the price sits at approximately 62% of its 52-week range ($1.21 to $24.28), indicating it has retreated significantly from its highs but remains well above its lows, suggesting a consolidation phase after a parabolic move. Recent momentum shows a sharp divergence, with a strong 30.0% gain over the past month contrasting with a slight 0.13% decline over the past three months, signaling a potential recovery attempt from the steep correction that occurred in late April. The stock exhibits high volatility, with a beta of 0.735 indicating it has been less volatile than the broader market during this period, though its own price history shows extreme swings, including a maximum drawdown of -59.5%. Key technical levels are clear, with immediate resistance near the recent highs around $22.47 and major support at the 52-week low of $1.21; a sustained breakout above the April highs would signal a resumption of the primary uptrend, while a breakdown below the $9-$10 consolidation zone could indicate further weakness.
Beta
0.73
0.73x market volatility
Max Drawdown
-59.5%
Largest decline past year
52-Week Range
$1-$24
Price range past year
Annual Return
+1296.2%
Cumulative gain past year
| Period | ERAS Return | S&P 500 |
|---|---|---|
| 1m | +42.4% | -2.0% |
| 3m | +13.0% | +13.9% |
| 6m | +391.7% | +8.7% |
| 1y | +1296.2% | +20.5% |
| ytd | +409.5% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ERAS Fundamental Analysis
As a pre-revenue clinical-stage biotech, Erasca's fundamental story is defined by its burn rate and pipeline progression rather than traditional sales growth, with quarterly revenue consistently at $0. The company reported a net loss of $29.1 million in Q4 2025, with an EPS of -$0.10, continuing a trend of operating losses typical for its development stage. Profitability metrics are not applicable, with gross, operating, and net margins all at 0%, and the focus is on the efficiency of its R&D spend, which was $23.2 million in the latest quarter. The balance sheet shows a strong liquidity position with a current ratio of 10.04 and cash of $74.2 million at the end of Q4 2025, but the company is burning cash aggressively, evidenced by a trailing twelve-month free cash flow of -$95.6 million and an operating cash flow of -$21.7 million in the last quarter; the debt-to-equity ratio of 0.145 is low, indicating minimal financial leverage, but the key fundamental question is the sufficiency of its cash runway to reach critical clinical catalysts without further dilution.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-95583000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ERAS Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric is the Price-to-Sales (PS) ratio, which is 0 due to the absence of revenue, making traditional multiples inapplicable. The trailing Price-to-Earnings (PE) ratio is -8.45 and the forward PE is -26.02, both negative and reflecting expected deepening losses, while the EV/EBITDA of -8.47 further confirms the challenge of applying earnings-based multiples. In the absence of meaningful peer multiples for a revenue-less company, valuation is entirely driven by the net present value of its pipeline and probability-adjusted clinical outcomes, which is not quantifiable from standard ratio data. Historically, the stock's own PE ratio has fluctuated wildly, from deeply negative levels above -100x in 2021 to its current -8.45x, but this historical context is of limited utility as the company's clinical prospects and associated risk profile have fundamentally evolved.
PE
-8.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -29x~-1x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-8.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ERAS faces severe financial risks inherent to its pre-revenue clinical stage. The company is burning cash aggressively, with a TTM free cash flow of -$95.6M and quarterly operating losses averaging ~$30M. With a cash balance of $74.2M, the implied runway is less than 12 months at the current burn rate, creating a high probability of a dilutive equity offering within the next year. Furthermore, the entire valuation is concentrated in two lead clinical programs (ERAS-0015 and ERAS-4001), meaning any clinical setback would have an outsized, immediate negative impact on the stock, as seen in the April 2026 sell-off.
Market & Competitive Risks: The primary market risk is valuation compression for clinical-stage biotechs in a rising interest rate environment, which discounts future cash flows more heavily. While the stock's beta of 0.735 suggests it has been less volatile than the market recently, its own history shows extreme idiosyncratic volatility tied to clinical news. Competitively, the RAS/MAPK pathway is a crowded and notoriously difficult area of oncology, with larger, better-funded competitors also pursuing similar targets. Any negative data readout or competitor success could trigger a sector-wide de-risking of ERAS's pipeline.
Worst-Case Scenario: The worst-case scenario involves a clinical failure of a lead program, leading to a cascade of analyst downgrades, a complete loss of investor confidence, and a rapid depletion of cash with no near-term path to revenue. This could trigger a sell-off back towards the 52-week low of $1.21, representing a potential loss of approximately -92% from the current price of $14.95. A more realistic severe adverse scenario, based on the recent -59.5% drawdown from the April high, suggests the stock could easily retest the $9-$10 support zone, implying a downside risk of -33% to -40% from current levels.
FAQ
The key risks are, in order of severity: 1) Clinical Trial Failure: The lead programs could fail, rendering the pipeline worthless and potentially sending the stock to its 52-week low of $1.21. 2) Financial/Dilution Risk: With a TTM cash burn of -$95.6M and $74.2M on hand, the company will need to raise capital soon, likely through a dilutive equity offering. 3) Competitive & Scientific Risk: The RAS/MAPK pathway is a competitive graveyard; a competitor's success or a shift in scientific understanding could obsolete ERAS's approach. 4) Market & Liquidity Risk: Limited analyst coverage and high short interest (short ratio of 5.96) can lead to exaggerated price moves and poor liquidity during sell-offs.
A 12-month forecast for ERAS involves three scenarios with a 25%/50%/25% probability split. The Bull Case (target $22.47-$30) assumes positive clinical data and a partnership. The Base Case (target $10-$18), which is most likely, assumes continued cash burn, a dilutive financing, and range-bound volatility on incremental news. The Bear Case (target $1.21-$9) assumes a clinical failure and a financing crisis. The base case is most probable because the company's finite cash runway makes a capital raise a near-term certainty, and the stock is likely to remain volatile but directionless until the next major clinical catalyst provides clarity.
ERAS cannot be valued using traditional metrics like P/E (currently -8.45) or P/S (0), as it has no earnings or revenue. Its valuation is entirely based on the probability-adjusted net present value of its clinical pipeline. The stock's violent price swings—from $1.21 to $24.28 and back to $14.95—demonstrate that the market's assessment of that value is highly volatile and sentiment-driven. Relative to its own history, it is fairly valued after its recent correction, trading midway between its extreme highs and lows. The market is currently pricing in a moderate chance of clinical success, but any new data will drastically re-set this implied probability.
ERAS is a speculative buy only for investors who understand and can tolerate extreme clinical and financial risk. The stock has massive potential upside (evidenced by its 983% annual gain) but equally massive downside risk (a -59.5% drawdown in months). The lack of revenue, aggressive cash burn (-$95.6M TTM), and binary dependence on clinical trial outcomes make it unsuitable for most portfolios. For a specialized biotech investor with a long time horizon and a portfolio structured to absorb losses, a small position could be justified, but it should not be considered a 'good buy' in the traditional sense of a sound investment.
ERAS is unsuitable for short-term trading for all but the most sophisticated and risk-tolerant investors due to its extreme volatility and event-driven nature. It is theoretically a long-term investment, but only if an investor has high conviction in the pipeline's ultimate success and is prepared to hold through multiple dilutive financings and clinical data cycles, which could take 3-5 years or more. The stock pays no dividend and offers no earnings visibility, so its only return potential is capital appreciation from clinical success. A realistic minimum holding period is 2-3 years to see through the next major clinical readout and financing event, but investors must be prepared for the possibility of a total loss.